Who is sponsoring NCT02456545?

NCT02456545 is sponsored by Technische Universität Dresden.

What drugs are being tested in NCT02456545?

Interventions in NCT02456545: ≥ 1 potential risk factor for BD, depressive syndrome, ADHD.

What condition does NCT02456545 study?

NCT02456545 studies Bipolar Disorder.

Is NCT02456545 still recruiting?

NCT02456545 is currently completed. Last updated 7 August 2024.

Last reviewed 2024-08-07 · How we verify

NCT02456545: BipoLife-A1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders

Completed Last updated 7 August 2024

What this trial tests

trial testing ≥ 1 potential risk factor for BD in Bipolar Disorder in 1,419 participants. Completed in 30 October 2020.

Timeline

3 June 2015

Primary endpoint
30 October 2020

30 October 2020

Quick facts

Lead sponsor	Technische Universität Dresden
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,419
Start date	3 June 2015
Primary completion	30 October 2020
Estimated completion	30 October 2020
Sites	9 locations across Germany

Drugs / interventions tested

≥ 1 potential risk factor for BD
depressive syndrome
ADHD

Conditions studied

Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

Technische Universität Dresden — full company profile →

Who can join

Adults 15 to 35, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective multicentre observational study for treatment approaches in at-risk individuals. Furthermore the purpose of this study is to test feasibility of a clinical staging model and validate diagnostic tools to identify individuals at risk state for the development of BD.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Aims and structure of the German Research Consortium BipoLife for the study of bipolar disorder.
Ritter PS, Bermpohl F, Gruber O, Hautzinger M, et al · · 2016 · cited 32× · PMID 27873290 · DOI 10.1186/s40345-016-0066-0
The German research consortium for the study of bipolar disorder (BipoLife): a magnetic resonance imaging study protocol.
Vogelbacher C, Sommer J, Schuster V, Bopp MHA, et al · · 2021 · cited 7× · PMID 34786613 · DOI 10.1186/s40345-021-00240-6
Creativity and transition to bipolar disorder: a prospective analysis from the early-bipolife study.
Michaelis E, Bauer M, Bechdolf A, Bermpohl F, et al · · 2025 · PMID 41469505 · DOI 10.1186/s40345-025-00406-6
Quality of life in persons at risk for bipolar disorder: a two year prospective-longitudinal observational cohort study (BipoLife).
Glaus J, Karow A, Lambert M, Sowada P, et al · · 2025 · PMID 39964389 · DOI 10.1186/s40345-025-00373-y
The German research consortium for the study of bipolar disorder (BipoLife): a quality assurance protocol for MR neuroimaging data.
Vogelbacher C, Sommer J, Bopp MHA, Falkenberg I, et al · · 2024 · PMID 39327338 · DOI 10.1186/s40345-024-00354-7

Verify or expand the search:

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting

Other Technische Universität Dresden trials

Trials by the same sponsor.

NCT07150598 — Immune-Marker Platform for Patients With Advanced Lung Cancer · not yet recruiting
NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
NCT06701487 — Role of Pavlovian Mechanisms for Control Over Substance Use · recruiting
NCT03865277 — Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging · Phase 2 · not yet recruiting
NCT06293170 — Automated Screening for Clinically Ascertained Loss of Cerebral Functions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02456545 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technische Universität Dresden
Last refreshed: 7 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02456545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing